Rekvina Laboratories held its 1st Extra-Ordinary General Meeting for FY2026-27 on April 10, 2026, with six resolutions put to vote.
All six resolutions were passed, including increasing authorized share capital and two preferential share issuances (one for cash, one non-cash).
Shareholder approval was obtained for investments/loans/guarantees exceeding Section 186 limits and for related party transactions.
Voting occurred via e-voting from April 6-9, 2026, with 62.81% of total outstanding shares represented across all resolutions.